Because of these similarities within BRCA1-mutated breast cancer, we hypothesized that some neoantigens may be found recurrently across individuals with BRCA1 mutations and may be used as neoantigens for off-the-shelf cancer vaccines, both for therapeutic purposes for cases with somatic BRCA1 mutations, and for preventive purposes for those with germline BRCA1 mutations. This evidence concerns the gene BRCA1 and breast carcinoma.